Erythromycin, known by its CAS number 114-07-8, is a critically important compound in the pharmaceutical industry, serving as both an Active Pharmaceutical Ingredient (API) and a key intermediate for various drug formulations. Its well-established antibacterial properties and versatility make it a sought-after chemical for drug manufacturers worldwide.

As an API, Erythromycin is directly incorporated into medications designed to combat bacterial infections. Its efficacy against a broad spectrum of pathogens has cemented its place in treating conditions ranging from respiratory and skin infections to more specific ailments like diphtheria and pertussis. The macrolide structure of Erythromycin is central to its function, allowing it to inhibit protein synthesis in bacteria by targeting the 50S ribosomal subunit. This targeted action ensures that it effectively disrupts bacterial replication without significantly harming human cells.

Beyond its role as an API, Erythromycin also functions as a valuable pharmaceutical intermediate. It can be chemically modified or used as a building block in the synthesis of other related antibiotics or drug compounds. This dual functionality underscores its importance in the drug development and manufacturing pipeline. For companies seeking to procure Erythromycin, understanding its properties and applications is essential for ensuring product efficacy and safety.

Suppliers and manufacturers, particularly those based in China, play a pivotal role in ensuring the global availability of high-quality Erythromycin. When sourcing this compound, pharmaceutical companies prioritize purity, consistent batch-to-batch quality, and reliable delivery. Manufacturers who adhere to stringent quality control protocols and international regulatory standards are highly valued. The wholesale price of Erythromycin can vary, but the investment is justified by its critical role in producing effective treatments for bacterial diseases, contributing significantly to public health outcomes globally.